AlphaQuest LLC Acquires Shares of 23,399 AVANOS MEDICAL, INC. $AVNS

Key Points

• AlphaQuest LLC has acquired a new position in Avanos Medical, purchasing 23,399 shares valued at approximately $335,000.
• Avanos Medical's stock price rose 2.7%, trading at $11.89, with a market cap of $551.79 million.
• Avanos Medical reported earnings of $0.17 per share, which missed the consensus estimate by $0.01, and set FY 2025 guidance at 0.750-0.950 EPS.

AlphaQuest LLC purchased a new stake in shares of AVANOS MEDICAL, INC. (NYSE:AVNS - Free Report) during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 23,399 shares of the company's stock, valued at approximately $335,000. AlphaQuest LLC owned 0.05% of AVANOS MEDICAL at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also modified their holdings of the business. Martingale Asset Management L P increased its stake in AVANOS MEDICAL by 18.3% in the 1st quarter. Martingale Asset Management L P now owns 123,883 shares of the company's stock valued at $1,775,000 after buying an additional 19,186 shares during the period. T. Rowe Price Investment Management Inc. grew its holdings in shares of AVANOS MEDICAL by 24.8% during the 1st quarter. T. Rowe Price Investment Management Inc. now owns 3,757,576 shares of the company's stock valued at $53,847,000 after acquiring an additional 746,264 shares in the last quarter. EntryPoint Capital LLC acquired a new position in shares of AVANOS MEDICAL in the first quarter worth $181,000. Quantbot Technologies LP raised its holdings in shares of AVANOS MEDICAL by 782.1% during the first quarter. Quantbot Technologies LP now owns 35,442 shares of the company's stock worth $508,000 after acquiring an additional 31,424 shares in the last quarter. Finally, American Century Companies Inc. raised its holdings in shares of AVANOS MEDICAL by 17.0% during the first quarter. American Century Companies Inc. now owns 122,947 shares of the company's stock worth $1,762,000 after acquiring an additional 17,835 shares in the last quarter. Institutional investors and hedge funds own 95.17% of the company's stock.

Wall Street Analyst Weigh In

AVNS has been the topic of several research reports. Wall Street Zen lowered AVANOS MEDICAL from a "strong-buy" rating to a "buy" rating in a research report on Saturday, August 9th. Zacks Research upgraded AVANOS MEDICAL to a "hold" rating in a report on Tuesday, August 12th. One equities research analyst has rated the stock with a Hold rating, Based on data from MarketBeat, AVANOS MEDICAL has an average rating of "Hold".

Insider Buying and Selling at AVANOS MEDICAL

In other news, Director Gary Blackford bought 40,000 shares of the firm's stock in a transaction that occurred on Wednesday, August 13th. The shares were acquired at an average cost of $10.99 per share, with a total value of $439,600.00. Following the completion of the transaction, the director directly owned 40,000 shares in the company, valued at $439,600. This represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 2.64% of the company's stock.

AVANOS MEDICAL Stock Performance

Shares of AVANOS MEDICAL stock traded up $0.06 during trading on Monday, reaching $11.93. The company's stock had a trading volume of 647,282 shares, compared to its average volume of 820,234. The business's fifty day moving average price is $11.62 and its 200-day moving average price is $12.80. AVANOS MEDICAL, INC. has a one year low of $9.30 and a one year high of $25.36. The firm has a market cap of $553.74 million, a price-to-earnings ratio of -1.19 and a beta of 1.12. The company has a debt-to-equity ratio of 0.12, a quick ratio of 1.58 and a current ratio of 2.64.

AVANOS MEDICAL (NYSE:AVNS - Get Free Report) last announced its quarterly earnings data on Tuesday, August 5th. The company reported $0.17 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.18 by ($0.01). The company had revenue of $175.00 million during the quarter, compared to analyst estimates of $165.50 million. AVANOS MEDICAL had a positive return on equity of 6.16% and a negative net margin of 66.89%.During the same quarter in the previous year, the business posted $0.34 EPS. AVANOS MEDICAL has set its FY 2025 guidance at 0.750-0.950 EPS. As a group, equities research analysts predict that AVANOS MEDICAL, INC. will post 1.32 earnings per share for the current year.

AVANOS MEDICAL Profile

Avanos Medical, Inc, a medical technology company, offers medical device solutions in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. It offers a portfolio of chronic care products that include digestive health products, such as Mic-Key enteral feeding tubes, Corpak patient feeding solutions, and NeoMed neonatal and pediatric feeding solutions.